Surfactant-BL / Biosurf - LARVOL DELTA

Efficacy and Safety of Nebulized Surfactant-BL as a Part of Complex Therapy of COVID-19-associated ARDS: A Multicenter, Open-label Randomized Controlled Trial (ATS 2023) - "Our study demonstrates that the use of nebulized surfactant is feasible in non-intubated patients with CARDS, and its application results in favorable outcomes, such as shortening of the mean duration of oxygen therapy and improved oxygenation. Treatment with inhaled surfactant is well tolerated."

Clinical • Surfactant • Acute Respiratory Distress Syndrome • Infectious Disease • Inflammation • Novel Coronavirus Disease • Respiratory Diseases